Jeffrey Freeman, DO
Endocrinology, Diabetes & Metabolism · Springfield, PANPI 1831127091
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,710 of the $218,918 with a category attached, or 81.2%. 60 manufacturers reported payments, led by Novo Nordisk at 52.3% of the total. Reporting peaked in 2019 at $88,918 and has fallen 87.1% since, to $11,490 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,287 payments — averaging $170.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$115K
- Amarin Pharma, Inc.$44K
- Bayer$22K
- Amgen$12K
- Mannkind Corporation$5K
- Valeritas, Inc.$4K
- plus $17K from 54 others
Across 7 payments — averaging $881.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$6K
What the payments were for
- Consulting fees$6,8953%
- Speaking & faculty fees$177,71081%
- Travel & lodging$7,7734%
- Food & beverage$25,98412%
- Education$4380%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$45,190
- Vascepa$42,072
- RYBELSUS$40,194
- Kerendia$20,993
- Xultophy 100/3.6$10,963
- Tresiba$10,387
- Repatha$9,543
- V-GO$4,282
- AFREZZA$2,572
- JARDIANCE$2,200
- SOLIQUA 100/33$602
- MINIMED 780G$158
- NATPARA (PARATHYROID HORMONE)$125
- CYCLOSET$107
- PRALUENT$107
- UNITY DIABETES MANAGEMENT SYSTEM$106
How this compares
$218,918 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 263 | $401,270 |
| JardianceEmpagliflozin | 203 | $244,688 |
| TrulicityDulaglutide | 137 | $213,951 |
| FarxigaDapagliflozin Propanediol | 111 | $131,050 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $102,452 |
| JanuviaSitagliptin Phosphate | 74 | $87,434 |
| RybelsusSemaglutide | 41 | $84,695 |
| KerendiaFinerenone | 62 | $84,505 |
| MounjaroTirzepatide | 65 | $74,553 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $62,382 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $58,317 |
| VascepaIcosapent Ethyl | 62 | $50,364 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 26 | $39,484 |
| Novolog FlexpenInsulin Aspart | 144 | $37,640 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $37,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $114,549 | $495,584338 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $2,044 | $295,165231 claims |
| Boehringer IngelheimJardiance | $2,728 | $244,688203 claims |
| AstraZenecaFarxiga | $386 | $131,050111 claims |
| MerckJanuvia, Janumet | $497 | $109,96593 claims |
| BayerKerendia | $21,607 | $84,50562 claims |
| Mannkind CorporationAfrezza | $4,504 | $25,78746 claims |
| AbbVieSynthroid | $338 | $13,987177 claims |
| Esperion Therapeutics, Inc.Nexlizet | $232 | $8,45414 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $108 | $7,873656 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Springfield
- Sonum SinghSpringfield$16K
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.